Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: An historical population based cohort study

B. M. Roede*, P. Bresser, P. J.E. Bindels, A. Kok, M. Prins, G. Ter Riet, R. B. Geskus, R. M.C. Herings, J. M. Prins

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

50 Citations (Scopus)


Objectives: The risk of a subsequent exacerbation after treatment of an exacerbation with oral corticosteroids without (OS) or with (OSA) antibiotics was evaluated in a historical population based cohort study comprising patients using maintenance medication for obstructive lung disease. Methods: The Pharmo database includes drug dispensing records of more than 2 million subjects in The Netherlands. Eligible were patients ≥50 years who in 2003 were dispensed ≥2 prescriptions of daily used inhaled β2 agonists, anticholinergics and/or corticosteroids, and experienced at least one exacerbation before 1 January 2006. Exacerbation was defined as a prescription of OS or OSA. The times to the second and third exacerbations were compared using Kaplan-Meier survival analysis. Independent determinants of new exacerbations were identified using multivariable Cox recurrent event survival analysis. Results: Of 49 599 patients using maintenance medication, 18 928 had at least one exacerbation; in 52%, antibiotics had been added. The OS and OSA groups were comparable for potential confounding factors. Median time to the second exacerbation was 321 days in the OS group and 418 days in the OSA group (p<0.001); and between the second and third exacerbation 127 vs 240 days (p<0.001). The protective effect of OSA was most pronounced during the first 3 months following treatment (hazard ratio (HR) 0.62; 99% Cl 0.60 to 0.65). In the OSA group, mortality during follow-up was lower (HR 0.82; 99% Cl 0.66 to 0.98). Conclusion: Treatment with antibiotics in addition to oral corticosteroids was associated with a longer time to the next exacerbation, and a decreased risk of developing a new exacerbation.

Original languageEnglish
Pages (from-to)968-973
Number of pages6
Issue number11
Publication statusPublished - Nov 2008
Externally publishedYes

Bibliographical note

The study was supported by an unrestricted grant from ‘‘PICASSO for
COPD’’, an initiative of Pfizer, Boehringer Ingelheim and the research institute Caphri
(Care and Public Health Research Institute) from the University of Maastricht, The
Netherlands (project 004).
The funding source had no role in the design or conduct of the study, collection,
management, analysis, or interpretation of the data, or preparation, review or approval
of the manuscript.


Dive into the research topics of 'Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: An historical population based cohort study'. Together they form a unique fingerprint.

Cite this